Brand Name : Soranib
Available Dose : 200 mg
Composition : Sorafenib Tosylate
Manufactured by : Cipla Ltd
Dosage Form : Tablets
Packing : Pack of 120 Tablets
Soranib belongs to a class of multi kinase inhibitors, the main ingredient which is used as sorafenib. It is not used as curable medicine but Soranib is used to reduce the growth rate of cancer cells by barrier the actions of an aberrant protein signal transduction helps to develop the cancer cells. Soranib is mechanism by depleting the blood supply to the cancer cells and stop their division and production.
The Soranib Tablets usual dose is 400 mg (2 x 200 mg tablets)
• Soranib administrated twice daily on empty stomach (at least 1 hour before or 2 hours after a meal).
• The therapy should continue untill the patient is not clinically benefiting from the treatment.
Soranib abolish the surface of cell and intracellular kinase to lag the development of tumor cells. Soranib work as a biological treatment which is a inhibitor of protein kinase which is an enzyme ( chemical messenger). This enzyme enhance grow of tumor cells.
Soranib which will also work as multi kinase inhibitor, Since Soranib stops the protein kinase. It has two way actions,
1. Soranib will aim the protein which normally help to develop the malignant cells.
2. Soranib helps to block cancer cells forming from new blood vessels.
Soranib tablet when compared to oral solution the mean bioavailability is 38-49% after absorption. The time to high plasma level of Soranib is 3hrs. Therefore Soranib is administrated without food.
The drug Soranib has human plasma protein bounding is 99.5%
In liver CYP3A4, Soranib go through metabolism of oxidative and in glucuronidation by UGT1A9. Soranib has totally 8 metabolite are found in which 5 metabolite present in serum.
In oral administration, the total dose excreted 96% within 14 days, and elimination of dose via feces 77% and dose in urine 19% as glucuronidated.
Soranib interaction with carbamazepine + dexamethasone + Phenobarbital + phenytoin + rifamipicin leads to reduce in Sorafenib plasma concentration. Soranib interaction with doxorubicin and irinotecan will increase the plasma concentration.
The patients is contraindicated to hypersensitivity reaction then avoid using Soranib tablet Carboplatin and paclitaxel interaction with Soranib will cause to squamous cell lung cancer.
It is unknown that this medicine passes into breast milk or could harm a new born baby. Avoid using of Soranib medication, if your breast feeding.
Stored at 25℃ Place in cool and dry place and protect from light and heat. Dispense in its original container and close it tightly. Soranib should keep away from children.
To confirm the Using of Soranib medicine is safe for the patient , Inform the doctor if you have any of these other conditions:
• kidney or liver problems other than cancer
• high BP
• Cardiac problems
• a history of stroke
If you are allergic to Sorafenib (the active ingredients)
SORAFENIB SIDE EFFECTS
Common Sorafenib Side Effects: mouth dryness ; throat soreness ; Tiredness :Acne ; Dry skin ; Nausea ; Itching or rash skin ; Vomiting, ; Diarrhea ; Patchy hair thinning, ; decreased appetite ; Stomach pain ; etc.
Serious Side Effects : Chest heavy feeling ; Sudden weakness ; Increased blood pressure ; Bloody stools ; Coughing up blood / vomit ; fast heart rate ; low concentration ;; dermatology problem; jaundice etc. Mechanism of action: Sorafenib is an oral anti-cancer drugs, and also an inhibitor of various protein kinases, as such as VEGFR, PDGFR and Raf family kinases, because of usage in different kinases it is commonly known for multikinase enzyme inhibitor that decreases cell proliferation in vitro, researchers still made to improve sorafenib mechanism of action to behave as effective inhibitor.